Reimbursement Review Reports

The latest Reimbursement Review reports are posted to this page. Our Reimbursement Reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.

For each drug, plasma product, or cell and gene therapy reviewed in the Drug Reimbursement Review process, there is an opportunity for patient groups and clinician groups to provide input and feedback. See Reimbursement Review Open Calls for Input and Feedback.

Brand Name Sort descending Generic Name Therapeutic Area Recommendation Type Project Status Date Submission Received Date Recommendation Issued
Humira Adalimumab ulcerative colitis Withdrawn
Humira Adalimumab Arthritis, Rheumatoid List with clinical criteria and/or conditions Complete
Humira Adalimumab Arthritis, Psoriatic List with clinical criteria and/or conditions Complete
Humira Adalimumab Ankylosing spondylitis (AS) List with clinical criteria and/or conditions Complete
Humira Adalimumab Crohn's disease List with clinical criteria and/or conditions Complete
Humira Adalimumab Arthritis, juvenile idiopathic List with clinical criteria and/or conditions Complete
Humira Adalimumab Psoriasis List with clinical criteria and/or conditions Complete
Humira Adalimumab Hidradenitis suppurativa Reimburse with clinical criteria and/or conditions Complete
Humira Adalimumab Ulcerative colitis Do not list at the submitted price Complete
HyQvia immune globulin human and recombinant human hyaluronidase Humoral immunodeficiency Reimburse with clinical criteria and/or conditions Complete